Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Italy.
A. Nocivelli Institute for Molecular Medicine Spedali Civili and Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
J Alzheimers Dis. 2022;87(3):991-997. doi: 10.3233/JAD-215646.
Plasma phosphorylated tau species have been recently proposed as peripheral markers of Alzheimer's disease (AD) pathology. In this cross-sectional study including 91 subjects, plasma and cerebrospinal fluid (CSF) p-tau181 and p-tau231 levels were elevated in the early symptomatic stages of AD. Plasma p-tau231 and p-tau181 were strongly related to CSF phosphorylated tau, total tau and amyloid and exhibited a high accuracy-close to CSF p-tau231 and p-tau181-to identify AD already in the early stage of the disease. The findings might support the use as diagnostic and prognostic peripheral AD biomarkers in both research and clinical settings.
血浆磷酸化 tau 物种最近被提议作为阿尔茨海默病 (AD) 病理的外周标志物。在这项包括 91 名受试者的横断面研究中，AD 早期症状阶段的血浆 p-tau181 和 p-tau231 水平升高。血浆 p-tau231 和 p-tau181 与 CSF 磷酸化 tau、总 tau 和淀粉样蛋白密切相关，在疾病早期具有很高的准确性-接近 CSF p-tau231 和 p-tau181-用于识别 AD。这些发现可能支持将其用作研究和临床环境中 AD 的诊断和预后外周生物标志物。
